Here's What's Pushing Up Esperion Therapeutics Inc. Today [The Motley Fool]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: The Motley Fool
Positive top-line results for Esperion's lead candidate are giving investors a reason to cheer. Cory Renauer ( TMFang4apples ) Aug 8, 2017 at 12:46PM What happened Shares of Esperion Therapeutics Inc. ( NASDAQ:ESPR ) , a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead candidate. The stock was up 19.8% as of 11:10 a.m. EDT during Tuesday's session. So what Esperion's wagons are tightly circled around bempedoic acid, its only drug in clinical trials at the moment. This morning, the company announced results from a 60-patient mid-stage study that met its main goal with flying colors. Image source: Getty Images. LDL cholesterol levels among patients treated for six weeks with a triple combination containing bempedoic acid, Zetia, and Lipitor fe
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 [Yahoo! Finance]Yahoo! Finance
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- ESPR's page on the SEC website